E-ISSN 2667-8721

Is Methylprednizalone a Predisposing Factor for Bacterial and Fungal Infections in Critical Patients due to COVID-19?

Aim: The COVID -19 outbreak was first seen in Wuhan, China’s Hubei province. Lung infections caused by COVID-19; It can progress to severe ARDS (acute respiratory distress syndrome) with a high mortality.For ARDS patients, methylprednisolone (1-2 mg / kg per day) is recommended to be as short as possible.

Methods: All patients with a diagnosis of covid-19 over the age of 18 who were hospitalized in the pandemic intensive care unit between March 2020 and September 2020 were retrospectively screened.Patients; demographic data, hospitalization APACHE II scores, length of stay in hospital and intensive care, laboratory values (d-dimer, creatinine, CRP (C reactive protein)), culture results, mortality and morbidity, mechanical ventilator needs. On the first day of intensive care admissions, methylprednizalone was added to the treatment intravenously at 0.5 mg/kg/day for 5 days.

Results: A total of 201 patients hospitalized in adult level 3 intensive care were included in the study. All patients were PCR positive. 44.8% of the patients were female (n: 90), 55.2% were male (n: 111). Blood, urine and ETA cultures; there was no statistically significant relationship between gender, IMV need, mortality and prednol use.

Conclusion: COVID-19 is a viral infectious disease that manifests mainly as fever and pneumonia. Corticosteroid therapy; in addition, it includes the following risks: hyperglycemia, poor wound healing, psychosis, pancreatitis, and prolonged muscle weakness in impaired functional status in a meta-analysis published in 2012, nine randomized controlled trials, 1001 patients were included. Consequently, the use of corticosteroids did not decrease mortality.

Keywords: Methylprednisolone, bacterial and fungal infections, COVID-19


Eurasian J Critical Care 2021; 3 (1):21-24
Original Article